• Mutation; HGNC; 1097; BRAF; Simple; p.Gly469Val (c.1406G>T); ClinVar=VCV000044803; Zygosity=Heterozygous (PubMed=23401075).
  
• Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (PubMed=24035680).
  
• Mutation; HGNC; 12362; TSC1; Simple; p.Gln55Ter (c.163C>T); ClinVar=VCV000048808; Zygosity=Homozygous (PubMed=23401075).
  

PubMed=6244232
Williams R.D.
Human urologic cancer cell lines.
Invest. Urol. 17:359-363(1980)

PubMed=3708594
Masters J.R.W., Hepburn P.J., Walker L., Highman W.J., Trejdosiewicz L.K., Povey S., Parkar M., Hill B.T., Riddle P.N., Franks L.M.
Tissue culture model of transitional cell carcinoma: characterization of twenty-two human urothelial cell lines.
Cancer Res. 46:3630-3636(1986)

PubMed=3800330
Debiec-Rychter M., Christensen B., Kieler J., Wang C.Y.
Chromosomal characterization and isoenzyme pattern of non-malignant and malignant human urothelial cell lines.
Anticancer Res. 6:1237-1244(1986)

PubMed=7905254
Christensen B., Hansen C., Kieler J., Schmidt J.
Identity of non-malignant human urothelial cell lines classified as transformation grade I (TGrI) and II (TGrII).
Anticancer Res. 13:2187-2191(1993)

PubMed=8900435; DOI=10.1002/(SICI)1097-0215(19961009)68:2<239::AID-IJC17>3.0.CO;2-5
Klopocki A.G., Krop-Watorek A., Dus D., Ugorski M.
Adhesion of human uroepithelial cells to E-selectin: possible involvement of sialosyl LewisA-ganglioside.
Int. J. Cancer 68:239-244(1996)

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459
Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.
Short tandem repeat profiling provides an international reference standard for human cell lines.
Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

PubMed=15846775; DOI=10.1002/gcc.20166
Williams S.V., Adams J., Coulter J., Summersgill B.M., Shipley J.M., Knowles M.A.
Assessment by M-FISH of karyotypic complexity and cytogenetic evolution in bladder cancer in vitro.
Genes Chromosomes Cancer 43:315-328(2005)

PubMed=23401075; DOI=10.1002/path.4176
Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L., Kwiatkowski D.J.
TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.
J. Pathol. 230:17-27(2013)

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057
Hurst C.D., Platt F.M., Knowles M.A.
Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.
Eur. Urol. 65:367-369(2014)

PubMed=29732388; DOI=10.3233/BLC-180167; PMCID=PMC5929350
Zuiverloon T.C.M., de Jong F.C., Costello J.C., Theodorescu D.
Systematic review: characteristics and preclinical uses of bladder cancer cell lines.
Bladder Cancer 4:169-183(2018)

PubMed=30193179; DOI=10.1016/j.jmbbm.2018.08.036
Raczkowska J., Prauzner-Bechcicki S.
Discrimination between HCV29 and T24 by controlled proliferation of cells co-cultured on substrates with different elasticity.
J. Mech. Behav. Biomed. Mater. 88:217-222(2018)